ALDX - Kala Pharmaceuticals: Targeting Dry Eye Disease
Kala Pharmaceuticals (KALA) is a small-cap biopharma with one product already in the market and one about to have a PDUFA on August 15, 2019. These products are in the ocular disease segment, and while the approved product, INVELTYS, is merely a steroid approved for post-surgical use, the lead pipeline product seems to have more potential in relieving certain dry eye disease symptoms. Overall, we like the focus on a less competitive area, and the fact that they have been able to get something approved, with another on the line. Make no mistake,